Both HCPs and patients reported stable QoL evaluation scores up to 1 year of Optune use1,2,*,†
- HCP-reported KPS and patient-reported Global Health Status were
- Maintained from baseline through 12 months of follow-up
- Comparable with the TMZ alone arm
*HCP-reported data collected per KPS assessment at baseline and then repeated monthly. Patient functional status via KPS (at multiple time points) measured patient independence in activities of daily living.
† Patient-reported data collected per EORTC QLQ-C30 at baseline and Months 3, 6, 9, and 12. This 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).
- In the pivotal study, patients were treated with the first model of Optune, which was twice as large in size and weight (6 lb) than the currently available device (2.7 lb)
Physical, Role, Social, Emotional, and Cognitive Functioning for patients treated with Optune + TMZ all remained stable and comparable with the TMZ alone arm2
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core quality of life questionnaire; HCPs, healthcare professionals; HRQoL, health-related quality of life; KPS, Karnofsky Performance Score; QoL, quality of life; TMZ, temozolomide.
References: 1. Zhu JJ, Demireva P, Kanner AA, et al. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J Neurooncol. 2017;135:545-552. 2. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082. 3. EORTC Quality of Life Group. EORTC QLQ-C30, Version 3.0. 1995. European Organisation for Research and Treatment of Cancer, Belgium.